GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Gyre Therapeutics Inc.
Shares of Gyre Therapeutics, a biotech focused on liver disease treatments, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for chronic liver diseases. We've classified it in the "Pharma: Liver" segment. The chart below shows the overall performance of biotech companies working in this complex and promising field.
Broad Market Index - GURU.Markets
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for chronic liver diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
GYRE - Daily change in the company's share price Gyre Therapeutics Inc.
Shares of Gyre Therapeutics, a biopharmaceutical company, are exhibiting the extreme volatility typical of the sector. change_co tracks investor reactions to clinical trial news. This parameter is key for building high-risk asset valuation models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma liver
Gyre Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with GYRE, which focuses on liver disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Gyre is a biopharmaceutical company specializing in liver disease treatments. This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical Gyre's dynamics are for this niche.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Gyre Therapeutics Inc.
Gyre is a biopharmaceutical company specializing in the treatment of liver diseases. Its shares are driven by news of clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma liver
Gyre Therapeutics is a biotech company focused on developing drugs for liver diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gyre Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Gyre Therapeutics Inc.
Donegal, a regional insurance company. The monthly fluctuations on the chart reflect price cycles in the insurance market. Losses from weather events in the regions where it operates, such as winter storms, are a significant factor affecting its profitability.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Gyre Therapeutics focuses on liver diseases, occupying a highly specialized niche in biotechnology. The pharmaceutical sector's momentum is often driven by research breakthroughs and regulatory approvals. Gyre's story is a bet on the success of its scientific developments, which have the potential to change patients' lives and stand out from the industry landscape.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for liver diseases. The company's future depends solely on the success of its clinical trials and regulatory approvals. The broader market chart serves as a mere backdrop to illustrate how news about its scientific developments has driven its stock in its own world.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Gyre Therapeutics Inc.
Gyre Therapeutics (formerly Catalyst Biosciences) is a biotech company. Its weekly stock price, like that of many companies in the sector following a strategy shift, is extremely volatile and dependent on news about its new development pipeline.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Gyre Therapeutics is a biotech company. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart below shows how news about its clinical trials drives its stock price movement independently of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Gyre, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how its stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
GYRE - Market capitalization of the company Gyre Therapeutics Inc.
Gyre Therapeutics' market cap is a focused bet on liver disease treatments. This biotech's stock price reflects investor expectations for its key experimental drugs. Its volatility is a direct market reaction to news of clinical trials, which could shape the company's future.
GYRE - Share of the company's market capitalization Gyre Therapeutics Inc. within the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of liver and lung fibrosis. Its market share reflects the potential of its leading pipeline in this complex area. The chart below shows how the market assesses its chances of developing effective drugs.
Market capitalization of the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of chronic liver diseases. The chart below shows the overall market capitalization of the pharmaceutical sector. It illustrates the scale of the market Gyre is targeting and the potential of its developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the fight against a rare liver disease. Gyre Therapeutics is developing drugs to treat pulmonary arterial hypertension associated with portal hypertension. Its volatile line on the chart reflects the hopes of patients and investors for success in this narrow and complex area of medicine.
Book value capitalization of the company, segment and market as a whole
GYRE - Book value capitalization of the company Gyre Therapeutics Inc.
Gyre Therapeutics' book value is derived from its financial reserves and intellectual property in drugs for the treatment of liver fibrosis. This represents focused scientific capital. The chart shows how the biotech company manages its research budget during the development and clinical testing of its lead candidates.
GYRE - Share of the company's book capitalization Gyre Therapeutics Inc. within the market segment - Pharma liver
Gyre Therapeutics is a biotech company focused on treating liver diseases. Currently, its assets consist of intellectual property and research data. The chart shows a minimal share of physical assets, typical for a company in clinical development.
Market segment balance sheet capitalization - Pharma liver
Developing drugs for liver disease, like Gyre Therapeutics', is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Gyre Therapeutics' assets are not factories, but primarily intellectual property and capital focused on developing drugs for liver diseases. The book value reflects the company's financial resources for clinical trials. The chart illustrates the scale of this small biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Gyre Therapeutics Inc.
For Gyre, a small biotech company, market capitalization represents the belief in its liver disease treatments. The ratio to book value (its cash value) reflects the premium the market is willing to pay for the potential success of its developments in this complex field.
Market to book capitalization ratio in a market segment - Pharma liver
Gyre Therapeutics is a biotech company focused on treating liver diseases. Its high valuation on this chart reflects investors' bet on the success of its clinical development in a complex medical area with an unmet need.
Market to book capitalization ratio for the market as a whole
Gyre Therapeutics is a clinical-stage biotech focused on treating fibrotic liver diseases. Its valuation is based on the success of its lead drug in clinical trials. This metric demonstrates how high investor expectations can be for companies targeting large markets with unmet medical needs.
Debts of the company, segment and market as a whole
GYRE - Company debts Gyre Therapeutics Inc.
Gyre Therapeutics, a clinical-stage biopharmaceutical company, relies entirely on external funding to advance its development. Debt instruments can serve as a bridge between equity rounds, allowing research to continue. This chart reflects the high valuations and financial uncertainty in the world of biotech startups.
Market segment debts - Pharma liver
Gyre Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases, particularly fibrosis. This chart shows how the company raises capital to fund its expensive and lengthy clinical trials, a standard model for biotech companies without commercial products.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company developing drugs for the treatment of liver diseases. The path from scientific concept to approved drug requires significant financial investment and is fraught with high risks. This chart illustrates the company's reliance on debt to finance its lengthy and expensive clinical trials.
Market segment debt to market segment book capitalization - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for chronic liver diseases, an area with significant unmet needs. This chart shows how the company is funding its long-term clinical trials, relating its debt structure to the broader biotech landscape.
Debt to book value of all companies in the market
Gyre Therapeutics (formerly Catalyst Biosciences) has shifted its focus to treating liver diseases. This shift in biotech strategy requires new financing. How dependent will the company be on debt to advance its new developments? This graph of total debt in the economy provides context for assessing its financial vulnerability at this critical juncture.
P/E of the company, segment and market as a whole
P/E - Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs for chronic liver diseases. This chart illustrates the promise and risks associated with finding effective treatments for fibrosis. The valuation is highly sensitive to clinical trial data and regulatory decisions.
P/E of the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company specializing in developing drugs for the treatment of chronic liver diseases. This chart shows the average valuation for the sector, providing investors with context for assessing the scientific potential and risks associated with developing drugs for the treatment of liver diseases.
P/E of the market as a whole
Gyre Therapeutics is a biopharmaceutical company focused on treating liver diseases. The valuation of such companies often takes on a life of its own, depending on the success of clinical trials. Does comparing this chart reveal the extent to which Gyre investors are ignoring the broader market picture, betting solely on its scientific potential?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of liver fibrosis. This chart reflects analyst and investor expectations regarding the success of its clinical trials. Future revenue is entirely dependent on regulatory approvals and the commercial potential of its developments.
%20P%2FE%20Gyre%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Gyre-Therapeutics-Inc.&v=1772702516759 "Chart of the company's future (projected) P/E Gyre Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma liver
Gyre Therapeutics is a late-stage biopharmaceutical company developing drugs for the treatment of chronic liver diseases, specifically primary biliary cholangitis (PBC). This chart reflects industry expectations, allowing for a comparison of how the market perceives the approval and commercial success of Gyre's key drug compared to competitors.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772702516786 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Gyre Therapeutics, Inc. is a biopharmaceutical company specializing in the treatment of liver diseases. Like many companies in this sector, its valuation depends on the success of clinical development. This chart of overall risk appetite shows how willing investors are to invest in long-term and risky biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702516787 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company focused on treating liver diseases, particularly chronic hepatitis B. While in clinical development, the company is incurring significant losses. This chart illustrates the long and expensive journey to developing innovative drugs to address global health problems.
Profit of companies in the market segment - Pharma liver
Gyre Therapeutics is focused on developing drugs for chronic liver diseases. This chart, reflecting the financial health of the pharmaceutical sector, is important to them as an indicator of the investment climate. Positive dynamics in the industry help them attract capital for expensive clinical trials, which determine the future of their developments.
Overall market profit
Gyre Therapeutics is focused on developing drugs for liver fibrosis, an area with unmet medical needs and significant market potential. The success of such biotech companies depends on research results and access to capital. Overall economic stability, reflected in this chart, is important for attracting long-term investment in the sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for liver diseases, particularly chronic hepatitis B. Its future depends on the success of clinical trials. This chart summarizes analyst opinions on the likelihood of their therapy being approved and its potential commercial success in the vast Asian market.
%20profit%20of%20the%20company%20Gyre%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Gyre-Therapeutics-Inc.&v=1772702516854 "Graph of future (projected) profit of the company Gyre Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma liver
Gyre Therapeutics (formerly Catalyst Biosciences) is a biopharmaceutical company focused on developing treatments for liver diseases. Following a strategic shift, its future depends on the success of new clinical programs. This biotech chart reflects overall investor sentiment and their willingness to fund companies in early-stage research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772702516866 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Gyre Therapeutics, a biopharmaceutical company, treats liver diseases. Its success depends primarily on clinical data. However, the overall economic environment reflected in this forecast influences the investment climate in the sector and the strategic decisions of major pharmaceutical companies that may partner with it.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702516873 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company specializing in developing treatments for fibrotic liver diseases. For a clinical-stage company, this chart is key. It shows how investors evaluate the potential future sales of its drugs, betting on success in an area of high medical need.
P/S market segment - Pharma liver
Gyre Therapeutics specializes in developing drugs for the treatment of chronic liver diseases. Being in the clinical stage, the company's valuation is based on the future potential of its developments. This chart reflects the average valuation in the biotech sector, providing investors with context for understanding market expectations for Gyre's scientific platform.
P/S of the market as a whole
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for chronic liver diseases, specifically primary biliary cholangitis. This chart, which reflects market revenue estimates, serves as a benchmark for Gyre's expectations. It shows the value investors place on the potential of its lead drug to solve an important medical problem.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for liver diseases. For clinical-stage companies, the future is everything. This chart reflects investor assessments of the likelihood of clinical trial success and the commercial potential of its developments, which could carve out a niche in the market.
%20P%2FS%20Gyre%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Gyre-Therapeutics-Inc.&v=1772702516904 "The graph of the company's future (projected) P/S Gyre Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for chronic liver diseases, including primary sclerosing cholangitis (PSC). This chart reflects average future revenue expectations in the pharmaceutical sector. It provides an insight into the market's perception of Gyre's potential in treating rare liver diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772702516907 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Gyre Therapeutics is a biotech company specializing in developing treatments for liver diseases. This chart reflects overall investor sentiment. Gyre's success in clinical trials could bring new treatments to market for millions of patients, contributing to overall investor optimism about the potential of the entire biopharmaceutical industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702516922 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Gyre Therapeutics Inc.
This chart illustrates the revenue of Gyre Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases. At this stage, its revenue may be minimal and comes from partnerships rather than commercial sales, reflecting progress in research and development.
Sales of companies in the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs to treat fibrotic liver diseases such as nonalcoholic steatohepatitis (NASH). This graph illustrates the potential size of the hepatology market. Successful development of an effective therapy could radically change treatment approaches and create a huge new segment in the pharmaceutical industry.
Overall market sales
Gyre Therapeutics is a biopharmaceutical company developing treatments for liver diseases. Its prospects depend on the success of clinical trials. The overall economic climate, reflected in this chart, influences the investment climate in the biotech sector, which influences the company's funding.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Gyre Therapeutics Inc.
Gyre Therapeutics is a biopharmaceutical company focused on the treatment of liver diseases. Its revenue forecast is based on the expected success of its lead candidate's clinical trials. The chart reflects analysts' confidence in the commercial potential of its hepatology developments.
%20sales%20of%20the%20company%20Gyre%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Gyre-Therapeutics-Inc.&v=1772702516965 "Schedule of future (projected) sales of the company Gyre Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs to treat chronic liver diseases such as fibrosis. The need for effective therapies in this area is enormous. This chart shows the forecast for the entire pharmaceutical market, where liver diseases represent a major and growing opportunity for innovative companies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772702516975 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Gyre Therapeutics (formerly Catalyst Biosciences) is focused on developing drugs for the treatment of liver diseases. The company's future depends entirely on the results of its clinical programs and strategic decisions. This chart illustrates the overall investment climate, but for Gyre Therapeutics, achieving scientific goals that can create significant value regardless of market cycles is key.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702516985 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Gyre Therapeutics Inc.
Gyre Therapeutics is a biotech company focused on developing drugs for liver diseases. While in clinical trials, it incurs significant R&D expenses. This chart shows its net losses—investments in research aimed at solving complex medical problems and creating future revenue streams.
Market segment marginality - Pharma liver
Gyre Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of fibrotic liver diseases. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors analyze it to assess the company's potential to address complex liver disease problems.
Market marginality as a whole
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of fibrotic liver diseases, such as primary sclerosing cholangitis. This overall profitability curve is irrelevant to them. Their future depends entirely on the results of clinical trials and the potential of their drugs to become a new standard of care in their niche.
Employees in the company, segment and market as a whole
Number of employees in the company Gyre Therapeutics Inc.
Gyre Therapeutics is a biotech company focused on treating liver diseases. Its small team consists of scientists and clinical development specialists. An increase on this chart would signal progress in clinical trials and the expansion of its research activities.
Share of the company's employees Gyre Therapeutics Inc. within the market segment - Pharma liver
Gyre Therapeutics is a biotech company focused on developing drugs for the treatment of chronic liver diseases. This chart reflects the company's workforce profile in its highly specialized pharmaceutical niche. The dynamics of this metric reflect the scale of its ongoing clinical trials, as each phase of testing involves a growing team of scientists, physicians, and researchers.
Number of employees in the market segment - Pharma liver
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs to treat liver diseases caused by fibrosis. This chart shows employment trends in the highly specialized field of hepatology. The growing number of scientists and clinicians in this field signals progress in clinical research and the growing need for treatments for chronic liver diseases.
Number of employees in the market as a whole
Gyre Therapeutics is a biopharmaceutical company focused on developing treatments for chronic liver diseases, particularly fibrosis. It strives to offer new solutions for patients with limited treatment options. This chart demonstrates how innovations in treating common diseases are driving research and creating jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Gyre Therapeutics Inc. (GYRE)
Gyre Therapeutics is a biotech company specializing in liver diseases. This chart reflects the market's valuation of its intellectual capital. The company's value, like that of many biotechs, is based on the potential of its drug candidates in clinical trials. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Gyre%20Therapeutics%20Inc.%20(GYRE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Gyre-Therapeutics-Inc.-GYRE&v=1772702517111 "Chart of market capitalization per employee (in thousands of dollars) of the company Gyre Therapeutics Inc. (GYRE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on developing drugs for liver diseases. Its value is determined by the potential of its clinical programs. This chart shows the high market valuation of its research assets and prospects based on its small team of scientists, which is typical for biotech companies.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772702517113 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Gyre Therapeutics (formerly Catalyst Biosciences) is a biopharmaceutical company focused on developing treatments for liver diseases. The chart reflects the company's valuation at the clinical stage. The company's entire value is derived from the hope for the success of its developments. This indicator demonstrates the value the market places on the work of a small team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702517122 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Gyre Therapeutics Inc. (GYRE)
Gyre Therapeutics is a clinical-stage biotech company specializing in drugs for the treatment of liver fibrosis. This research is highly intensive. This chart shows the research intensity: the amount of capital spent on each scientist attempting to solve complex medical problems.
%20Chart%20Gyre%20Therapeutics%20Inc.%20(GYRE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Gyre-Therapeutics-Inc.-GYRE&v=1772702517136 "Company Profit Per Employee (in thousands of dollars) Chart Gyre Therapeutics Inc. (GYRE)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Gyre Therapeutics (GYRE) is a clinical-stage biotech company focused on treating liver diseases. This loss per employee reflects the high cost of R&D and clinical trials in this complex therapeutic area.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772702517145 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Gyre Therapeutics is a clinical-stage biotech company specializing in the treatment of fibrotic diseases (including the liver). It's an R&D company. Like Inventiva, the company is profitless. This chart shows the company's capital burn rate: the operating loss per research team developing the new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702517151 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Gyre Therapeutics Inc. (GYRE)
Gyre Therapeutics is a biopharmaceutical company focused on treating fibrotic liver diseases. This chart reflects the progress of its research commercialization. Currently, revenue is likely coming from partnerships, and the increase in revenue per employee signals the achievement of important clinical milestones.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Gyre-Therapeutics-Inc.-GYRE&v=1772702517158 "Sales chart per company employee Gyre Therapeutics Inc. (GYRE)")
Sales per employee in the market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company specializing in developing treatments for liver diseases. For a clinical-stage company, this chart shows how efficiently their research team generates revenue (e.g., from partnerships) per employee, compared to other companies in the segment.
Sales per employee for the market as a whole
Gyre Therapeutics (GYRE) is a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases. The company does not yet have commercial revenue. This chart illustrates a classic R&D scenario: a team of highly qualified scientists working on the development of future drugs consumes investment capital.
Short shares by company, segment and market as a whole
Shares shorted by company Gyre Therapeutics Inc. (GYRE)
Gyre Therapeutics, Inc. is a biotech company focused on treating liver and lung fibrosis. This chart shows bearish sentiment. As with other biotechs in this field (such as Inventiva), investors are betting that its candidates will fail to prove their efficacy in challenging clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Gyre-Therapeutics-Inc.-GYRE&v=1772702517192 "Short Shares Chart for the Company Gyre Therapeutics Inc. (GYRE)")
Shares shorted by market segment - Pharma liver
Gyre Therapeutics is a biotech company focused on treating liver diseases. This chart shows bearish sentiment. The "shorts" here are betting that their key drug (Hydronidone) will fail to prove effective in clinical trials or receive FDA approval.
Shares shorted by the overall market
Gyre Therapeutics is a clinical-stage biotech focused on liver diseases. Like all companies in the pre-profit era, Gyre is entirely dependent on external funding. When this graph shows a rise in general market fear, the "cash spigot" for biotechs is turned off, and the risk of bankruptcy becomes real.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Gyre Therapeutics Inc. (GYRE)
Gyre Therapeutics (GYRE) is a biotech company focused on treating liver diseases, particularly IgA nephropathy (kidney disease) and related conditions. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) due to R&D delays or setbacks, which is typical for this sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Gyre-Therapeutics-Inc.-GYRE&v=1772702517215 "RSI 14 indicator chart for the company's stock Gyre Therapeutics Inc. (GYRE)")
RSI 14 Market Segment - Pharma liver
Gyre Therapeutics (GYRE) is a biotech company specializing in liver disease treatment. The RSI_14_Seg for the "Pharma liver" (biotech) segment shows the overall sentiment. The chart helps us understand: is GYRE's volatility a reaction to its clinical trials, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
Gyre Therapeutics (GYRE) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GYRE (Gyre Therapeutics Inc.)
Gyre Therapeutics is a biotech company focused on treating fibrotic liver diseases, including progressive fibrosis associated with hepatitis C. This chart shows the analysts' average 12-month forecast, representing their collective, speculative bet on the success of the company's clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GYRE-Gyre-Therapeutics-Inc.&v=1772702517226 "A chart showing analyst consensus forecasts for the expected stock price. GYRE (Gyre Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price GYRE (Gyre Therapeutics Inc.)
Gyre Therapeutics is a clinical-stage biotech focused on developing drugs for chronic liver disease (fibrosis). This is a high-risk R&D bet. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the scientific potential of the company's R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GYRE-Gyre-Therapeutics-Inc.&v=1772702517247 "A chart showing the difference between the consensus forecast and the actual stock price. GYRE (Gyre Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Gyre Therapeutics is a biopharmaceutical company focused on the treatment of liver diseases, particularly fibrosis caused by metabolic disorders. This chart shows analysts' overall expectations for the liver pharma sector. It reflects whether experts believe a breakthrough in the treatment of NASH and other liver diseases is possible.
Analysts' consensus forecast for the overall market share price
Gyre Therapeutics is an R&D biotech burning cash in search of a cure for liver disease (NASH). This chart, which measures analyst consensus on the market, represents risk appetite. If the consensus is negative (downturn), investors flee speculative biotechs, making it harder for GYRE to raise capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Gyre Therapeutics Inc.
Gyre Therapeutics is a clinical-stage biotech focused on treating liver diseases. This chart is a pure indicator of biotech expectations. It doesn't reflect current revenue, but rather an aggregated assessment of their scientific data, clinical trial progress, and market confidence in their R&D pipeline's ability to address these complex medical challenges.
AKIMA Market Segment Index - Pharma liver
Gyre Therapeutics (GYRE) is a clinical-stage biotech focused on liver diseases (NASH/MASH) and other fibrotic diseases. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D focus on liver diseases (GYRE) differentiate it from the average pharma company?
The AKIM Index for the overall market
Gyre Therapeutics is a biotech company focused on treating fibrosis and inflammatory liver diseases (NASH/MASH). It has strong ties to China. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story compares to overall economic trends that influence risk appetite.
